Atrial fibrillation (AFib) is the most common heart rhythm disorder, causing the upper chambers of the heart to quiver chaotically instead of beating in coordination. Beyond the symptoms of fatigue and palpitations, it raises the risk of stroke and heart failure significantly.
What's actually going on in research
Catheter ablation — using heat or cold energy to destroy the abnormal tissue driving AFib — has become the preferred rhythm-control strategy for many patients and is being refined to improve long-term success rates. Newer direct oral anticoagulants continue to be studied for durability and safety in special populations including those with kidney disease or at very high bleeding risk. Left atrial appendage closure devices are being compared against long-term blood thinners in patients who cannot safely take anticoagulants.
Catheter ablation advances
Pulsed-field ablation — a newer energy form that targets heart tissue more selectively than heat — is being compared with thermal ablation for safety and long-term AFib freedom.
Anticoagulation refinement
Trials are testing optimal anticoagulation strategies in AFib patients with chronic kidney disease, after ablation, and after stroke to balance bleeding and clot risk.
Appendage closure devices
Implantable devices that close off the left atrial appendage — where most AFib-related clots form — are being compared to blood thinners in patients at high bleeding risk.
What to know before you search
Eligibility depends on AFib type (paroxysmal, persistent, permanent), stroke risk score (CHA2DS2-VASc), prior ablation attempts, kidney function, and bleeding history.
What types of trials are currently open
- Ablation trials — Comparing catheter ablation approaches, energy types, and lesion sets for AFib rhythm control.
- Drug trials — Testing antiarrhythmic medications and anticoagulants in different AFib populations.
- Device trials — Evaluating implantable monitors, pacemakers, and left atrial appendage closure devices.
- Lifestyle trials — Testing weight loss, exercise, alcohol reduction, and sleep apnea treatment on AFib burden.
- Heart failure trials — Testing rhythm vs. rate control strategies in AFib patients with concurrent heart failure.
Recently added Atrial Fibrillation trials
REPRESENT-PF Registry
This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.
Remote ECG Monitoring Post TAVI
The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.
Find Atrial Fibrillation trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.